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Summary Between January 1991 and December 1992 a phase I trial of superficial photodynamic therapy
(PDT) using topical application of 5-aminolaevulinic acid (ALA) was undertaken to treat Bowen's disease,
superficial basal cell carcinomas (BCCs) and metastatic skin secondaries from breast (adenocarcinoma) or
pinna (squamous cell carcinoma). Promising results were obtained with 36 areas of Bowen's disease, with a
complete response rate of 89% at a median follow-up of 18 months. The treatment of BCCs was less
successful, with 50% complete responses in 16 lesions at a median follow-up of 17 months. Metastatic nodules
responded poorly. The treatment was well tolerated and discomfort during light irradiation could be reduced
by prior application of 'Emla' cream. Lesions wept for 1-2 weeks following treatment and healed over a
period of approximately 2 months. For large areas of Bowen's disease, particularly in anatomically difficult
areas and in elderly patients, PDT using ALA may constitute a single simple alternative outpatient treatment
to existing therapies. Further work is required to improve the results with BCCs.
Non-melanoma primary skin cancer is the most common
malignancy affecting man (White, 1992), and the skin is also
a frequent site of metastatic spread. Photodynamic therapy
has been investigated as a new modality for the treatment of
both primary and secondary skin cancer. This form of
therapy uses a combination of photosensitiser, light and
oxygen to kill tumour cells (Moan & Berg, 1992).
Haematoporphyrin derivative and its more purified successor
Photofrin (P-II) are the sensitisers on which most clinical
work has focused. For treatments using these sensitisers and
superficial light illumination, complete response (CR) rates of
88% (Wilson et al., 1992) and 100% (Kennedy, 1983) have
been reported for basal cell carcinomas (BCCs). Similarly,
Bowen's disease is reported to have a CR rate of 100%
(Carruth & Williams, 1991; Jones et al., 1992), and Gilson et
al. (1988) have achieved CR rates of 74% for metastatic skin
nodules from a variety of primary sites.
However, PDT using P-IT is associated with generalised
skin photosensitivity which persists for up to 8-10 weeks
following treatment (Dougherty et al., 1978). During this
period patients are advised to stay out of sunlight to avoid
developing severe sunburn. In addition, Photofrin-based
therapy may also cause significant damage to the normal
tissues lying adjacent to the tumour. Consequently, such
therapy cannot be considered ideal for the management of
primary skin cancer, for which a number of other forms of
treatment are available (e.g. excision, curettage, cautery,
cryotherapy, topical chemotherapy or radiotherapy).
A new form of PDT which avoids the problem of general-
ised skin photosensitivity has recently been developed by
Kennedy et al. (1990). This utilises the biochemical pathway,
present within every energy-producing cell in the body,
whereby haem is synthesised from glycine and succinyl CoA.
The direct precursor of haem in this pathway, protopor-
phyrin IX (PpIX), is thought to be the photosensitive species
upon which the new technique depends. Studies of haem
biosynthesis in the liver have indicated that the rate-limiting
step in the pathway is the conversion of glycine and succinyl
CoA to aminolaevulinic acid, and that this reaction is under
negative-feedback control by haem. Subsequently, it has been
shown that the systemic administration of excess exogenous
ALA can bypass this control point in both mice (Divaris et
al., 1990) and rats (Bedwell et al., 1992; Loh et al., 1992),
with a number of tissues developing a fluorescence spectrum
characteristic of PpIX and exhibiting histological damage
after illumination. Similarly, applying ALA cream to skin
cancers, but not normal undamaged skin, has been found to
result in the development of PpIX fluorescence (Kennedy et
al., 1990). Kennedy and Pottier (1992) applied 20% and 50%
ALA cream to superficial basal and squamous cell car-
cinomas and illuminated them with filtered light from a slide
projector. They report 79% CR rates at 3 months with basal
cell carcinomas.
This paper reports our work with superficial primary and
secondary skin cancer using ALA cream and 630 nm
light.
Materials and methods
Local ethical committee approval was obtained for these
studies, as was individual consent. ALA 20% (Sigma) dis-
solved in Unguentum Merck (E. Merck) was kindly made by
the Department of Pharmacy at Leeds General Infirmary.
Biopsies were done on single lesions before treatment but, if
the patient had more than two, biopsies were done on only a
representative lesion. Lesions were carefully examined and
measured, crusts removed and the surface lightly abraded
with forceps. A cloth cut-out was made to allow exposure of
the lesion and a 0.75 cm border of normal tissue to light.
Approximately 0.05 g of cream was applied per cm2 of skin,
and the lesion covered with a gauze dressing. Between 2 and
4 h after application of the ALA cream, 5% Emla cream
(lignocaine base 2.5% and prilocaine 2.5%, Astra Pharma-
ceuticals) was applied to the lesion with an occlusive dressing
and gauze covering. An hour after the Emla application,
tumours were irradiated with 630 nm light from a copper
vapour/dye laser (Oxford Lasers) using the cloth cut-out to
shield the surrounding normal skin. The light was focused
into a 600-nm-diameter optical fibre and imaged through a
lens system to produce a circular treatment area of uniform
intensity. Light doses of 125-250 J cm-2 were used, with the
irradiance being kept below 150 mW cm-2. The power of the
light emitted from the fibre was measured with a light meter
(Photon Control, Cambridge) before and after each treat-
ment. Following treatment, the area was covered with a
Release dressing. Approximately half of the lesions were
examined for fluorescence at time intervals of 3-6 h after
administering the cream. This was done in an entirely
qualitative manner by directing an ultraviolet dental probe at
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the lesion and looking for the red fluorescence of PpIX by
eye.
In 11 patients, in vivo dosimetry measurements of light
penetration were obtained and analysed. These results will be
reported in a future publication (E.J. Hudson et al. in
preparation).
Results
Details of the lesions treated are given in Table I. In cases in
which the clinical assessment was uncertain, punch biopsies
were taken for histological examination. Complete tumour
response was defined as absence of clinically evident tumour
at the site of treatment. Partial response was defined as 50%
reduction in tumour size as determined by clinical evaluation.
Treatment was reasonably well tolerated with Emla, although
one patient found it sufficiently uncomfortable for the treat-
ment to be terminated early. Some sensation was experienced
by the majority of patients during treatment. This com-
menced with the light, increased during the first 5 or 10 min
of treatment and subsequently decreased as treatment con-
tinued. It was variously described as, 'a worm wriggling
under the skin', 'burning', 'tingling', 'prickling' or as a 'bor-
ing sensation'. After treatment, primary skin tumours were
slightly oedematous and erythematous. Lesions usually wept
for 1-2 weeks, subsequently developed a light crust and
healed over 2-3 months. Little reaction was seen with metas-
tatic lesions.
Bowen's disease
The results for Bowen's disease are summarised in Table II,
which records response in relation to both light dose and the
time between the application of cream and exposure to light.
A complete response rate of 97% (35/36 lesions) was seen at
2 months, falling to 89% (32/36 lesions) at a median follow-
up of 18 months. A female patient with seven lesions was
treated by randomising the treatment parameters for each
lesion. This involved varying the time between application of
sensitising cream and illumination, as well as using two
different light doses. Her results are summarised in Table III.
All seven lesions responded completely with light doses
between 125 and 150 J cm-2 and time intervals between
cream and illumination of 3-5 h.
Fluorescence developed in Bowen's lesions about 3 h after
Table I Details of patients treated
No. of No. of Median size and Median follow-up
lesions patients range (cm) and range (months)
Bowen's disease 36 14 2 (0.5-7.5) 18 (7-22)
Basal cell carcinoma 16 14 2.1 (1-7) 17 (4-21)
Metastatic 14 5 1.1 (1-7.5) 10 (6-12)
adenocarcinoma
Metastatic squamous 6 1 0.7 (0.5-1.3) 9
cell carcinoma
Table II Responses of Bowen's lesions in relation to time between ALA
application and illumination, and light dose
Light dose Time between application of ALA and light (h)
(Jcm-2) 3-4 4-5 5-6
125 2 CR I CR
150 1 PR 20 CRs I CR
6 CR 1 CR followed by relapse
200 1 CR 1 CR
1 CR followed by relapse
>200 1 CR followed by relapse
Table III Response of one patient with seven areas of Bowen's disease
randomised to receive different light doses and time intervals between ALA cream
and illumination
Time between ALA Result at 13 months
Light dose (Jcm-2) and light (h) follow-up
125 3 CR
125 3.5 CR
125 4.5 CR
150 3 CR
150 3.75 CR
150 4.5 CR
150 5 CR
Table IV Responses of basal cell carcinomas in relation to time between ALA
application and illumination, and light dose
Light dose Time between application of ALA and light (h)
(Jcm-2) 3-4 4-5 5-6
150 2 CR 2 CR I CR
3 CR followed by relapse 2 CR followed by relapse
1 PR followed by relapse I PR followed by relapse
200 1 CR followed by relapse 2 CR 1 CRPDT FOR SUPERFICIAL SKIN CANCER 607
applying the ALA cream, and had disappeared by 6 h.
Figure 1 illustrates a large area of Bowen's disease before
and 16 months after treatment.
Basal cell carcinomas
These results are summarised in Table IV. A CR rate of 88%
(14/16 lesions) was seen at 2 months, falling to 50% (8/16
lesions) at a median follow-up of 17 months. Fluorescence
developed and disappeared as in the Bowen's lesions.
Metastatic adenocarcinomas
All these lesions were derived from primary breast car-
cinomas. One patient with six small (1 cm diameter) nodules
in her scalp achieved a CR in five, this being sustained for 6
months. These were treated with 150 J cm-2 of light and a
time interval between cream and light of 3-4.5 h. Although
eight other lesions were treated similarly, no other responses
were seen. Fluorescence was not observed in any lesion.
Metastatic squamous cell carcinomas
One patient with six metastatic nodules from a primary
carcinoma of the pinna was treated. In this case a dose of
150-200 Jcm2 of light and a time interval between cream
and light of 3-4 h was used. No response was achieved, nor
was any fluorescence observed.
Discussion
Primary skin cancer may be treated by a variety of tech-
niques (White, 1992). CR rates of 83%, 92% and 97% are
reported respectively for treatment of Bowen's disease with
surgery (Graham & Helwig, 1959), topical 5-fluorouracil
(Sturm, 1979) and superficial radiotherapy (Blank &
Schnyder, 1985). CR rates of 89.9%, 92.5% and 91.3% are
reported for the treatment of BCCs with surgical excision,
cryosurgery and radiotherapy respectively (Rowe et al.,
1989). For a new modality to become clinically acceptable it
must possess distinct advantages over existing treatments.
Our results with Bowen's disease are encouraging. Many
lesions are present in elderly patients with poorly vascularised
skin, and are often in areas relatively intolerant of radiation
such as the shin or ankle. This technique with ALA cream
and superficial light illumination offers a single outpatient
treatment and the reaction is mild. The vascularity of the
skin is not limiting. Although the number of patients in our
study is small, a light dose of 125 Jcm2 seems adequate
when combined with an interval of 3-5 h between cream and
light.
Our results with basal cell carcinomas (BCCs) are poor. In
their early report, Kennedy et al. (1990) quote a 90% CR for
BCCs at a follow up of 2-3 months. A more recent paper
(Kennedy & Pottier, 1992) gives a 3-month CR rate of 79%.
Another study has also reported high initial CR rates for
basal cell tumours (Wolf et al., 1993), but the median follow-
up was again short at 7 months. This present study reports
longer follow-up results with a relatively high rate of relapse
for BCCs. Reasons for these relapses may include insufficient
penetration by either cream or light (or both). The light
fluence needed for effective treatment is still the subject of
speculation. At present little is known about the penetration
of ALA cream through skin and tumours. Szeimies et al.
(1992) investigated fluorescence distribution in BCCs after
the topical application of 10% ALA in propylene glycol.
They found little fluorescence in the dermis. BCCs of solid
and superficial types showed homogeneous fluorescence in all
sections, whereas the morpheic variants demonstrated a
heterogeneous distribution.
While Bowen's disease is, by definition, intraepidermal,
BCCs histologically begin with small basal-like cells appar-
ently sprouting from the undersurface of intact epidermis
(McQueen & Smith, 1985). These may then communicate
a
b
Figure 1 Area of Bowen's disease in a patient a before and b 16
months after treatment.
with the epidermis. Thus, even the most superficial BCC is
likely to possess cells deeper than the epidermis, a possible
contributing factor towards the high relapse rate, given the
requirement for penetration by both drug and then light.608 F. CAIRNDUFF et al.
It should, in the future, prove possible to monitor the
distribution of PpIX fluorescence in skin tumours prior to
treatment with light, using fluorescence microscopy of punch
biopsies. We are currently investigating this possibility. It
may also be possible to improve PpIX distribution and
obtain dermal sensitisation by direct injection of ALA into
the tumour. Repeated treatments may also improve
results.
No reliable responses could be obtained with metastatic
skin disease, nor was any fluorescence seen. It is likely that
this may be because of inadequate penetration by the cream.
This may be improved by the use of intra-tumour injec-
tions.
Kennedy's original work was carried out using filtered
light from a slide projector (Kennedy et al., 1990). We chose
to use 630 nm light from a laser as the absorption spectrum
of protoporphyrin has a small peak at this wavelength (Pot-
tier et al., 1986). Although larger peaks are seen at shorter
wavelengths, the penetration of light in such spectral regions
is inferior, and absorption by haemoglobin is increased.
However, it may be possible to use other light sources to
treat skin tumours with topical ALA, and this would simplify
the treatment considerably. Indeed, it has been established, at
least in vitro, that irradiation of PpIX leads to its conversion
to two isomers of protoporphyrin - A and B (Bonnett et al.,
1980). These isomers are in fact chlorins with a much in-
creased and red-shifted absorption compared with PpIX.
Consequently, as has been suggested by Charlesworth and
Trusott (1993), combined-wavelength irradiation
(630 nm + 670 nm) may prove more effective than the single-
wavelength treatment used in the present study.
We feel that our results with Bowen's disease are
sufficiently encouraging for us to recommend its continuing
use in patients, particularly those with large or multiple
tumours which might be time-consuming and uncomfortable
to treat by other means. However, further work is required
to improve the results for BCCs, before ALA-based PDT
becomes a viable alternative treatment for this condition.
This work was generously supported by the Yorkshire Cancer
Research Campaign. We are also grateful to Dr Dave Roberts for
his helpful comments on the manuscript.
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